m m m m m
E NURSE PRESCRIBERS, 5TH EDITION TEST BANK FINAL EXAM QU
m m m m m m m m m
ESTIONS AND ANSWERS BEST RATED A+ GUARANTEED SUCCESS L
m m m m m m m m
ATEST UPDATE 2022 m m
Chapter 18. Drugs Affecting the Endocrine System: Pancreatic Hormones and Antidiabeti
m m m m m m m m m m
c Drugs
m
• Patients with cystic fibrosis are often prescribed enzyme replacement for pancreatic se
m m m m m m m m m m m
cretions. Each replacement drug has lipase, protease, and amylase components, but th
m m m m m m m m m m m
e drug is prescribed in units of:
m m m m m m
a. Lipase
b. Protease
c. Amylase
d. Pancreatin
• Brands of pancreatic enzyme replacement drugs are:
m m m m m m
a. Bioequivalent
b. About the same in cost per unit of lipase across brands
m m m m m m m m m m
c. Able to be interchanged between generic and brand-name products to reduce cost
m m m m m m m m m m m
d. None of the above m m m
• When given subcutaneously, how long until neutral protamine Hagedorn insulin begins to t
m m m m m m m m m m m m
ake effect (onset of action) after administration?
m m m m m m
a. 15 to 30 minutes m m m
b. 60 to 90 minutes m m m
c. 3 to 4 hours m m m
d. 6 to 8 hours m m m
• Hypoglycemia can result from the action of either insulin or an oral hypoglycemic. Signs
m m m m m m m m m m m m m m
NURS 60441 PHARMACOTHERAPEUTICS FOR ADVANCED PRACTIC
m m m m m
E NURSE PRESCRIBERS, 5TH EDITION TEST BANK FINAL EXAM QU
m m m m m m m m m
ESTIONS AND ANSWERS BEST RATED A+ GUARANTEED SUCCESS L
m m m m m m m m
ATEST UPDATE 2022 m m
,NURS 60441 PHARMACOTHERAPEUTICS FOR ADVANCED PRACTIC
m m m m m
E NURSE PRESCRIBERS, 5TH EDITION TEST BANK FINAL EXAM QU
m m m m m m m m m
ESTIONS AND ANSWERS BEST RATED A+ GUARANTEED SUCCESS L
m m m m m m m m
ATEST UPDATE 2022m m
and symptoms of hypoglycemia include:
m m m m
a. “Fruity” breath odor and rapid respiration m m m m m
b. Diarrhea, abdominal pain, weight loss, and hyp m m m m m m
ertension c. Dizziness, confusion, diaphoresis, and
m m m m m m
tachycardia
d. Easy bruising, palpitations, cardiac dysrhythmias, and coma
m m m m m m m
• Nonselective beta blockers and alcohol create serious drug interactions with insulin because th
m m m m m m m m m m m m
ey:
a. Increase blood glucose levels m m m
b. Produce unexplained diaphoresis m m
c. Interfere with the ability of the body to metaboliz
m m m m m m m m
e glucose d. Mask the signs and symptoms of altered
m m m m m m m m m m
glucose levels m
• Lispro is an insulin analogue produced by recombinant DNA technology.
m m m m m m m m m m
Which of the following statements about this form of insulin is NOT true
m m m m m m m m m m m m
?
a. Optimal time of preprandial injection is 15 minutes.
m m m m m m m
b. Duration of action is increased when the dose is increased.
m m m m m m m m m
c. It is compatible with neutral protamine Hagedorn insulin.
m m m m m m m
d. It has no pronounced peak.
m m m m
• The decision may be made to switch from twice daily neutral protamine Ha
m m m m m m m m m m m m
NURS 60441 PHARMACOTHERAPEUTICS FOR ADVANCED PRACTIC
m m m m m
E NURSE PRESCRIBERS, 5TH EDITION TEST BANK FINAL EXAM QU
m m m m m m m m m
ESTIONS AND ANSWERS BEST RATED A+ GUARANTEED SUCCESS L
m m m m m m m m
ATEST UPDATE 2022m m
,NURS 60441 PHARMACOTHERAPEUTICS FOR ADVANCED PRACTIC
m m m m m
E NURSE PRESCRIBERS, 5TH EDITION TEST BANK FINAL EXAM QU
m m m m m m m m m
ESTIONS AND ANSWERS BEST RATED A+ GUARANTEED SUCCESS L
m m m m m m m m
ATEST UPDATE 2022
m m
gedorn (NPH) insulin to insulin glargine to improve glycemia control throug
m m m m m m m m m m
hout the day. If this is done:
m m m m m m
a. The initial dose of glargine is reduced by 20% to avoid hypoglycemia.
m m m m m m m m m m m
b. The initial dose of glargine is 2 to 10 units per day.
m m m m m m m m m m m
c. Patients who have been on high doses of NPH will need tests for insulin antibodies.
m m m m m m m m m m m m m m
d. Obese patients may require more than 100 units per day.
m m m m m m m m m
• When blood glucose levels are difficult to control in type 2 diabetes some form
m m m m m m m m m m m m m m
of insulin may be added to the treatment regimen to control blood glucose and li
m m m m m m m m m m m m m m
mit complication risks.
m m
Which ofthe following statements is accurate based on research?
m m m m m m m m
a. Premixed insulin analogues are better at lowering HbA1C and have
m m m m m m m m m m
less risk for hypoglycemia.
m m m
b. Premixed insulin analogues and the newer premixed insulins are associat
m m m m m m m m m
ed with more weight gain than the oral antidiabetic agents.
m m m m m m m m m
c. Newer premixed insulins are better at lowering HbA1C and postpra
m m m m m m m m m
ndial glucose levels than long-acting insulins.
m m m m m
d. Patients who are not controlled on oral agents and have postprandial hy
m m m m m m m m m m m
perglycemia can have neutral protamine Hagedorn insulin added at bedti
m m m m m m m m m
me.
• Metformin is a primary choice of drug to treat hyperglycemia in type 2 diabetes because it:
m m m m m m m m m m m m m m m
a. Substitutes for insulin usually secreted by the m m m m m m m
pancreas b. Decreases glycogenolysis by the liver
m m m m m m
NURS 60441 PHARMACOTHERAPEUTICS FOR ADVANCED PRACTIC
m m m m m
E NURSE PRESCRIBERS, 5TH EDITION TEST BANK FINAL EXAM QU
m m m m m m m m m
ESTIONS AND ANSWERS BEST RATED A+ GUARANTEED SUCCESS L
m m m m m m m m
ATEST UPDATE 2022
m m
, NURS 60441 PHARMACOTHERAPEUTICS FOR ADVANCED PRACTIC
m m m m m
E NURSE PRESCRIBERS, 5TH EDITION TEST BANK FINAL EXAM QU
m m m m m m m m m
ESTIONS AND ANSWERS BEST RATED A+ GUARANTEED SUCCESS L
m m m m m m m m
ATEST UPDATE 2022 m m
c. Increasesmthemreleasemofminsulinmfrommbetamcells
d. Decreasesmperipheralmglucosemutilization
• Prior to prescribing metformin, the provider should:
m m m m m m
a. Draw a serum creatinine to assess renal function
m m m m m m m
b. Try the patient on insulin
m m m m
c. Tell the patient to increase iodine intake
m m m m m m
d. Have the patient stop taking any sulfonylurea to avoid dangerous drug interactions
m m m m m m m m m m m
• The action of “gliptins” is different from other antidiabetic agents because they:
m m m m m m m m m m m
a. Have a low risk for hypoglycemia
m m m m m
b. Are not associated with weight gain
m m m m m
c. Close ATP-dependent potassium channels in the beta cell
m m m m m m m
d. Act on the incretin system to indirectly increase insulin production
m m m m m m m m m
• Sitagliptin has been approved for:
m m m m
a. Monotherapy in once-daily doses m m m
b. Combination therapy with metformin m m m
c. Both 1 and 2
m m m m
d. Neither 1 nor 2 m m m
• GLP-1 agonists: m
a. Directly bind to a receptor in the pancreatic beta cell
m m m m m m m m m
b. Have been approved for monotherapy
m m m m
c. Speed gastric emptying to decrease appetite
m m m m m
NURS 60441 PHARMACOTHERAPEUTICS FOR ADVANCED PRACTIC
m m m m m
E NURSE PRESCRIBERS, 5TH EDITION TEST BANK FINAL EXAM QU
m m m m m m m m m
ESTIONS AND ANSWERS BEST RATED A+ GUARANTEED SUCCESS L
m m m m m m m m
ATEST UPDATE 2022 m m